|1.||Miyata, Toshio: 5 articles (01/2015 - 05/2010)|
|2.||Dan, Takashi: 3 articles (01/2015 - 05/2010)|
|3.||Ichimura, Atsuhiko: 3 articles (01/2015 - 05/2013)|
|4.||van Ypersele de Strihou, Charles: 2 articles (05/2013 - 05/2010)|
|5.||Kitatani, Kazuyuki: 1 article (01/2015)|
|6.||Toyoshima, Masafumi: 1 article (01/2015)|
|7.||Usui, Toshinori: 1 article (01/2015)|
|8.||Ishibashi, Masumi: 1 article (01/2015)|
|9.||Nagase, Satoru: 1 article (01/2015)|
|10.||Placencio, Veronica R: 1 article (01/2015)|
01/01/2012 - "In this study, we explored the therapeutic potential of an orally effective small molecule PAI-1 inhibitor, TM5275, in a model of lung fibrosis induced by transforming growth factor-β1 (TGF-β1), the most potent and ubiquitous profibrogenic cytokine, and in human lung fibroblasts (CCL-210 cells). "
01/01/2012 - "On the other hand, treating mice with 40 mg/kg of TM5275 for 10 days, starting 4 days after the instillation of AdTGF-β1(223/225), restored the activities of uPA and tPA and almost completely blocked TGF-β1-induced lung fibrosis, as shown by collagen staining, Western blotting, and the measurement of hydroxyproline. "
05/01/2010 - "Administered to a monkey model of photochemical induced arterial thrombosis, TM5275 (10 mg/kg) has the same antithrombotic effect as clopidogrel (10 mg/kg), without enhanced bleeding. "
05/01/2010 - "TM5275, administered orally in rats (1 to 10 mg/kg), has an antithrombotic effect equivalent to that of ticlopidine (500 mg/kg) in an arterial venous shunt thrombosis model and to that of clopidogrel (3 mg/kg) in a ferric chloride-treated carotid artery thrombosis model. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2015 - "The effect on tumor vasculature in vivo was further examined in endothelial cells (EC) in vitro and this analysis indicated that both TM5275 and TM5441 inhibited EC branching in a 3D Matrigel assay at concentrations where they had little effect on EC apoptosis. "
01/01/2015 - "Here we tested two orally bioavailable small molecule inhibitors of PAI-1 (TM5275 and TM5441) for their efficacy in pre-clinical models of cancer. "
|1.||Plasminogen Activator Inhibitor 1
|3.||Hydroxyproline (4 Hydroxyproline)